Johnson & Johnson (NYSE:JNJ) Price Target Cut to $175.00

Johnson & Johnson (NYSE:JNJ) had its price objective decreased by equities research analysts at Royal Bank of Canada from $181.00 to $175.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank of Canada’s price target indicates a potential upside of 20.08% from the stock’s current price.

A number of other analysts have also weighed in on the company. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Monday. Morgan Stanley decreased their price objective on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. Finally, Raymond James lifted their price objective on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $175.86.

Johnson & Johnson Stock Up 0.7 %

Shares of JNJ opened at $145.74 on Wednesday. The company has a market cap of $351.20 billion, a PE ratio of 9.09, a P/E/G ratio of 2.40 and a beta of 0.53. The business has a fifty day moving average of $156.32 and a 200 day moving average of $155.68. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The business had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. During the same quarter last year, the firm posted $2.68 earnings per share. The business’s revenue was up 2.3% compared to the same quarter last year. On average, sell-side analysts expect that Johnson & Johnson will post 10.65 EPS for the current year.

Insider Transactions at Johnson & Johnson

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Johnson & Johnson

A number of large investors have recently bought and sold shares of the company. Plimoth Trust Co. LLC boosted its position in Johnson & Johnson by 4.6% in the 1st quarter. Plimoth Trust Co. LLC now owns 34,163 shares of the company’s stock worth $5,404,000 after purchasing an additional 1,513 shares in the last quarter. Silverlake Wealth Management LLC boosted its position in Johnson & Johnson by 1.3% in the 1st quarter. Silverlake Wealth Management LLC now owns 24,449 shares of the company’s stock worth $3,868,000 after purchasing an additional 302 shares in the last quarter. Naviter Wealth LLC boosted its position in Johnson & Johnson by 43.8% in the 1st quarter. Naviter Wealth LLC now owns 20,281 shares of the company’s stock worth $3,208,000 after purchasing an additional 6,174 shares in the last quarter. Quattro Financial Advisors LLC boosted its position in Johnson & Johnson by 27,610.8% in the 1st quarter. Quattro Financial Advisors LLC now owns 43,506 shares of the company’s stock worth $6,882,000 after purchasing an additional 43,349 shares in the last quarter. Finally, MV Capital Management Inc. boosted its position in Johnson & Johnson by 5.3% in the 1st quarter. MV Capital Management Inc. now owns 18,942 shares of the company’s stock worth $2,996,000 after purchasing an additional 947 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.